ThermoGenesis Holdings Inc. (THMO) - יתרת חוב לטווח ארוך

The market price action of ThermoGenesis (THMO) reflects the dynamics of long-term liabilities, which currently stand at 0.00. The business relies on US-based plants that develop systems for regenerative therapy. Automated installations for biobanks generate revenue, creating demand for proprietary consumables. Consistent sales of stem cell processing cartridges ensure a steady cash flow and confirm the relevance of current technological solutions.

Assessing the reliability of equity assets begins with an analysis of the debt load. This indicator captures the total volume of credit obligations with a maturity of more than one year. For ThermoGenesis (THMO), such funds may be directed toward production modernization in line with ESG waste recycling standards. Rising borrowing increases financial risks as credit costs climb. The trend in the issuer's long-term liabilities allows for the determination of the balance between growth and stability.